Education Sessions
Challenges in Managing the Pre-Pandemic Influenza Vaccine Stockpile (HHS Perspective) (204)
| 28 October 14.15-17.15 | Track: Innovation |
ISPE CEUs: 0.2
(PDF Current as of 29 August 2008)
The U.S. Department of Health and Human Services (HHS) Pandemic Influenza Plan has invested almost $1 billion in the purchase of Influenza bulk vaccines for pandemic preparedness. This course will review the status of current stockpile and the selection of virus strains for the stockpile. The course will also review the current status of Avian Influenza in the world and the various virus strains in circulation. The impact of the genetic shifts in Avian Influenza and their impact on virus strain selection and current pre-pandemic bulk vaccine will be discussed. The HHS program to extend the prepandemic Influenza bulk through the use of adjuvants will also be reviewed. Lastly, the life cycle cost analysis developed by HHS/ASPR/BARDA for the stockpile program will be presented.
How You Will Benefit
At the end of this session, participants will be able to:
- Identify advances in vaccine technology development
- Describe scientific challenges still facing vaccine development and manufacture
- Describe scientific challenges still facing vaccine storage and stability
- Understand the value of the interface between immunology and vaccines for development breakthroughs
Who Should Attend
All persons interested in the department of Human Health and Services Pandemic Influenza Preparedness programs and their impact on the vaccine manufacturing community
ISPE Communities of Practice (COPs)
Biotechnology (Biotech), Containment, Disposables, Process/Product Development (PPD), Project Management (PM), and Sterile Products Processing (SPP)
Session Leader
- Thomas Warf, Program Manager, HHS/BARDA, USA
Session Speakers
- Armen Donabedian, Sr. Program Manager, Vaccines, HHS/OS/ASPR/BARDA, USA
- Robert Huebner, Senior Program Manager, HHS/OS/ASPR/BARDA, USA
- Robin Robinson, Director, HHS/OS/ASPR/BARDA, USA